15-epi-lxa4;15r-lxa4

15-epi-lxa4;15r-lxa4 is a lipid of Fatty Acyls (FA) class. 15-epi-lxa4;15r-lxa4 is associated with abnormalities such as Pneumonia, Septicemia, Cystic Fibrosis, Subarachnoid Hemorrhage and Obesity. The involved functions are known as Protective Agents, Signal Transduction, cytokine biosynthesis, Inflammation and Anabolism. 15-epi-lxa4;15r-lxa4 often locates in Blood, Immune system and Heart tissue. The associated genes with 15-epi-lxa4;15r-lxa4 are IL2 gene, CXCL13 gene and CMKLR1 gene. The related lipids are Steroids. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 15-epi-lxa4;15r-lxa4, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 15-epi-lxa4;15r-lxa4?

15-epi-lxa4;15r-lxa4 is suspected in Cystic Fibrosis, Asthma, Chagas Cardiomyopathy, Pneumonia, Septicemia, Subarachnoid Hemorrhage and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 15-epi-lxa4;15r-lxa4

MeSH term MeSH ID Detail
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Lung Diseases D008171 37 associated lipids
Inflammation D007249 119 associated lipids
Colitis D003092 69 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Edema D004487 152 associated lipids
Osteitis D010000 10 associated lipids
Asthma D001249 52 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Peritonitis D010538 38 associated lipids
Alzheimer Disease D000544 76 associated lipids
Hyperplasia D006965 34 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Glomerulonephritis D005921 35 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Nasal Polyps D009298 26 associated lipids
Hyperalgesia D006930 42 associated lipids
Toxoplasmosis D014123 9 associated lipids
Per page 10 20 50 | Total 32

PubChem Associated disorders and diseases

What pathways are associated with 15-epi-lxa4;15r-lxa4

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 15-epi-lxa4;15r-lxa4?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 15-epi-lxa4;15r-lxa4?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 15-epi-lxa4;15r-lxa4?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 15-epi-lxa4;15r-lxa4?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 15-epi-lxa4;15r-lxa4?

Knock-out

Knock-out are used in the study 'Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice.' (Ortiz-Muñoz G et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 15-epi-lxa4;15r-lxa4

Download all related citations
Per page 10 20 50 100 | Total 602
Authors Title Published Journal PubMed Link
Wu Y et al. Aspirin-triggered lipoxin Aâ‚„ attenuates lipopolysaccharide-induced intracellular ROS in BV2 microglia cells by inhibiting the function of NADPH oxidase. 2012 Neurochem. Res. pmid:22552474
Scully M et al. Protective role of cyclooxygenase (COX)-2 in experimental lung injury: evidence of a lipoxin A4-mediated effect. 2012 J. Surg. Res. pmid:21944479
Krönke G et al. The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. 2012 Ann. Rheum. Dis. pmid:22267335
Birnbaum Y et al. Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. 2012 Cardiovasc Drugs Ther pmid:22936458
Gangemi S et al. Ultrarush venom immunotherapy and the lipoxin a4 inflammation resolution pathway. 2012 Ann. Allergy Asthma Immunol. pmid:22920084
Xu Z et al. Lipoxin A4 inhibits the development of endometriosis in mice: the role of anti-inflammation and anti-angiogenesis. 2012 Am. J. Reprod. Immunol. pmid:22229383
Chinthamani S et al. Lipoxin A4 inhibits immune cell binding to salivary epithelium and vascular endothelium. 2012 Am. J. Physiol., Cell Physiol. pmid:22205391
Das UN Is lipoxins A₄ a better alternative to anti-VEGF and anti-TNF-α antibody to prevent and treat age-related macular degeneration, diabetic macular edema and retinopathy? 2012 Med. Sci. Monit. pmid:22207123
Bozinovski S et al. Serum amyloid A opposes lipoxin Aâ‚„ to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. 2012 Proc. Natl. Acad. Sci. U.S.A. pmid:22215599
Vong L et al. Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. 2012 PLoS ONE pmid:22723974
Zhou CH et al. [Protective effects and possible mechanism of lipoxin A(4) analogue in rats with acute pancreatitis]. 2012 Zhonghua Yi Xue Za Zhi pmid:22781577
Gilbert NC et al. Conversion of human 5-lipoxygenase to a 15-lipoxygenase by a point mutation to mimic phosphorylation at Serine-663. 2012 FASEB J. pmid:22516296
Gutierrez AD et al. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. 2012 Atherosclerosis pmid:22687642
Börgeson E et al. Lipoxin A4 attenuates adipose inflammation. 2012 FASEB J. pmid:22700871
Esper L et al. Role of SOCS2 in modulating heart damage and function in a murine model of acute Chagas disease. 2012 Am. J. Pathol. pmid:22658486
Verrière V et al. Lipoxin A4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia. 2012 PLoS ONE pmid:22662206
Jin H et al. Lipoxin A4 analog attenuates morphine antinociceptive tolerance, withdrawal-induced hyperalgesia, and glial reaction and cytokine expression in the spinal cord of rat. 2012 Neuroscience pmid:22366510
Gras D et al. An ex vivo model of severe asthma using reconstituted human bronchial epithelium. 2012 J. Allergy Clin. Immunol. pmid:22409990
Mumm JP Single-molecule microscopy of Cre recombination. 2012 Proc. Natl. Acad. Sci. U.S.A. pmid:23204438
Pertwee RG Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation. 2012 Proc. Natl. Acad. Sci. U.S.A. pmid:23204441
Pamplona FA et al. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. 2012 Proc. Natl. Acad. Sci. U.S.A. pmid:23150578
Lin F et al. Treatment of Lipoxin A(4) and its analogue on low-dose endotoxin induced preeclampsia in rat and possible mechanisms. 2012 Reprod. Toxicol. pmid:23063943
Sun T et al. LipoxinA(4) induced antinociception and decreased expression of NF-κB and pro-inflammatory cytokines after chronic dorsal root ganglia compression in rats. 2012 Eur J Pain pmid:21658981
Dakin SG et al. Macrophage sub-populations and the lipoxin A4 receptor implicate active inflammation during equine tendon repair. 2012 PLoS ONE pmid:22384219
Tsai WH et al. Role of lipoxin A4 in the cell-to-cell interaction between all-trans retinoic acid-treated acute promyelocytic leukemic cells and alveolar macrophages. 2012 J. Cell. Physiol. pmid:21567401
Zimmerman JJ Exhaled breath condensate: a breathalyzer for lung inflammation. 2012 Pediatr Crit Care Med pmid:22391827
Wu L et al. Lipoxin A4 inhibits 5-lipoxygenase translocation and leukotrienes biosynthesis to exert a neuroprotective effect in cerebral ischemia/reperfusion injury. 2012 J. Mol. Neurosci. pmid:22661361
Hasan RA et al. Lipoxin A(4) and 8-isoprostane in the exhaled breath condensate of children hospitalized for status asthmaticus. 2012 Pediatr Crit Care Med pmid:21666533
Jones CN et al. Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. 2012 Proc. Natl. Acad. Sci. U.S.A. pmid:23185003
Su X et al. Dysfunction of inflammation-resolving pathways is associated with exaggerated postoperative cognitive decline in a rat model of the metabolic syndrome. 2012 Mol. Med. pmid:23296426
Bitto A et al. Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis. 2012 Crit Care pmid:22356547
Dakin SG et al. Inflamm-aging and arachadonic acid metabolite differences with stage of tendon disease. 2012 PLoS ONE pmid:23155437
Rozsasi A et al. Cyclooxygenase 2 and lipoxin Aâ‚„ in nasal polyps in cystic fibrosis. 2011 Nov-Dec Am J Rhinol Allergy pmid:22185734
Levy BD et al. The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection. 2011 Jan-Feb Prostaglandins Leukot. Essent. Fatty Acids pmid:20869861
Zheng S et al. Novel biphasic role of LipoxinA(4) on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated lung fibroblasts. 2011 Mediators Inflamm. pmid:21765620
Börgeson E et al. Lipoxin A₄ and benzo-lipoxin A₄ attenuate experimental renal fibrosis. 2011 FASEB J. pmid:21628447
Walker J et al. Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis. 2011 Shock pmid:21701419
Hao H et al. Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. 2011 Cancer Lett. pmid:21683517
Ni CM et al. Serum levels of lipoxin A(4) do not predict the development of subsequent asthma among young children with acute bronchiolitis. 2011 J Asthma pmid:21671842
Chen H et al. Lipoxin A(4), a potential anti-inflammatory drug targeting the skin. 2011 J. Dermatol. Sci. pmid:21334856
Wu J et al. Lipoxin A4 inhibits the production of proinflammatory cytokines induced by β-amyloid in vitro and in vivo. 2011 Biochem. Biophys. Res. Commun. pmid:21501589
Das UN Lipoxin A4 may function as an endogenous anti-arrhythmic molecule. 2011 Med. Hypotheses pmid:20833483
Maldonado-Pérez D et al. A role for lipoxin A4 as anti-inflammatory and proresolution mediator in human parturition. 2011 FASEB J. pmid:20959513
Zhou M et al. The protective effects of Lipoxin A4 during the early phase of severe acute pancreatitis in rats. 2011 Scand. J. Gastroenterol. pmid:20950211
Khau T et al. Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2. 2011 FASEB J. pmid:20930115
Das UN Lipoxins as biomarkers of lupus and other inflammatory conditions. 2011 Lipids Health Dis pmid:21569625
Pang HY et al. [Effect of lipoxin A(4) on lipopolysaccharide-induced endothelial hyperpermeability in human umbilical vein endothelial cell]. 2011 Zhonghua Fu Chan Ke Za Zhi pmid:21575454
Russell R et al. Lipoxin A4 is a novel estrogen receptor modulator. 2011 FASEB J. pmid:21885654
Wang YP et al. Aspirin-triggered lipoxin A4 attenuates LPS-induced pro-inflammatory responses by inhibiting activation of NF-κB and MAPKs in BV-2 microglial cells. 2011 J Neuroinflammation pmid:21831303
Wan M et al. Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1. 2011 FASEB J. pmid:21307335